Katja F. Hellendahl
Papers
1
Total Citations
6
H-Index
1
About
Katja F. Hellendahl’s research lies at the intersection of biocatalysis and drug development, with a primary focus on nucleoside kinases (NKs)—enzymes critical for activating nucleoside analogues used in cancer and antiviral therapies. Her most cited work, a 2021 study introducing a semi-automated high-throughput substrate screening assay for NKs, represents a significant methodological advance. By streamlining the characterization of these enzymes, Hellendahl’s assay enables rapid identification of NK specificity, directly supporting rational drug design and the efficient in vitro production of nucleotide analogues. This contribution addresses a key bottleneck in nucleoside analogue research, where understanding enzyme-substrate interactions is essential for developing effective therapeutics. While her citation count is still growing, the practical impact of her work is evident in its potential to accelerate preclinical screening pipelines. Hellendahl’s approach exemplifies how automation and high-throughput techniques can bridge enzymology and applied pharmacology, offering a valuable tool for researchers working on targeted drug activation and synthetic biology. Her work positions her as an emerging voice in the field of enzyme engineering for medical applications.
Research Focus
Key Achievements
Top Papers
- 1